Breast Cancer, Post-Mastectomy
Conditions
Keywords
Mastectomy, Post-Mastectomy, Incentive Spirometer, Transcutaneous Electrical Diaphragmatic Stimulation
Brief summary
This randomized clinical trial will compare the effects of incentive spirometer therapy with and without transcutaneous electrical diaphragmatic stimulation (TEDS) in females who have undergone mastectomy. The study will include females aged 30 to 48 years who have undergone unilateral simple or radical mastectomy following breast cancer and are at least 3 months after surgery. Participants will be randomly assigned to one of two treatment groups. Participants in one group will receive conventional physiotherapy along with transcutaneous electrical diaphragmatic stimulation and incentive spirometer training. Participants in the other group will receive conventional physiotherapy and incentive spirometer training without TEDS. Treatment will be provided over 4 weeks. The study will evaluate changes in breathing-related symptoms, functional capacity, lung function, and quality of life. These outcomes will be assessed using a dyspnea index, Timed Up and Go test, pulmonary function testing (spirometry), and the Short Form-36 health survey. Assessments will be performed at baseline and after 4 weeks of treatment. The study aims to determine whether adding transcutaneous electrical diaphragmatic stimulation to incentive spirometer therapy provides additional benefits for post-mastectomy females.
Detailed description
Mastectomy is a surgical procedure used in the management of breast cancer. Following mastectomy, patients may experience changes in respiratory function, breathing patterns, functional capacity, and quality of life. This study will compare incentive spirometer therapy with and without transcutaneous electrical diaphragmatic stimulation (TEDS) in females following mastectomy. This study is designed as a randomized clinical trial. Participants will be recruited from Pink Ribbon Hospital and randomly allocated to two treatment groups using sealed-envelope randomization. The study will include females aged 30 to 48 years who have undergone unilateral simple or radical mastectomy, have a history of stage I to III breast cancer, are at least 3 months post-surgery, and have received chemotherapy or radiotherapy. Participants in Group A will receive conventional physiotherapy, transcutaneous electrical diaphragmatic stimulation, and incentive spirometer training. TEDS will be applied using surface electrodes placed over the lower rib cage. The intervention will be delivered using an electrical stimulation unit, with intensity adjusted to produce a visible or palpable diaphragmatic contraction without discomfort. Participants will also perform incentive spirometer exercises. Participants in Group B will receive conventional physiotherapy and incentive spirometer training without TEDS. Conventional physiotherapy will include diaphragmatic breathing, airway clearance exercises, circulatory exercises, thoracic expansion exercises, and postural awareness exercises. Treatment will be provided four times per week for 4 weeks. The primary areas of assessment will include dyspnea, functional capacity, pulmonary function, and quality of life. Dyspnea will be assessed using a 5-point Likert-based dyspnea index. Functional capacity will be assessed using the Timed Up and Go test. Pulmonary function will be assessed using spirometry, including measurements of forced vital capacity and expiratory volume. Quality of life will be assessed using the Short Form-36 questionnaire. Outcome assessments will be conducted at baseline and at the fourth week of the intervention. The study will evaluate whether adding TEDS to incentive spirometer therapy produces greater improvements in the measured outcomes compared with incentive spirometer therapy and conventional physiotherapy alone. The study protocol specifies a randomized allocation procedure using sealed envelopes and a single-blinded outcome assessment, in which the assessor is blinded to group allocation.
Interventions
Transcutaneous electrical diaphragmatic stimulation (TEDS) will be applied using surface electrodes placed over the lower rib cage. Electrical stimulation will be delivered using a portable electrical stimulation unit, with intensity adjusted to produce a visible or palpable diaphragmatic contraction without discomfort. TEDS will be provided to participants in the experimental group in addition to incentive spirometer training and conventional physiotherapy.
Participants will perform incentive spirometer breathing exercises in a half-lying position at approximately 45 degrees. The protocol describes repeated deep breaths with an inspiratory hold. Incentive spirometer training will be provided to both treatment groups during the 4-week intervention period, in addition to conventional physiotherapy.
Conventional physiotherapy will be provided to both groups and will include diaphragmatic breathing exercises, airway clearance exercises, circulatory exercises, thoracic expansion exercises, and postural awareness exercises. The conventional therapy component is described as a 20-minute session and will be provided four times per week for 4 weeks.
Sponsors
Study design
Masking description
The outcome assessor will be blinded to the treatment group allocation. Participants and care providers will not be masked to the intervention received.
Intervention model description
Participants will be randomly allocated to two parallel treatment groups. Group A will receive transcutaneous electrical diaphragmatic stimulation (TEDS), incentive spirometer training, and conventional physiotherapy. Group B will receive incentive spirometer training and conventional physiotherapy without TEDS. Treatment will be provided for 4 weeks, with assessments performed at baseline and at the fourth week.
Eligibility
Inclusion criteria
* Participants aged 30 to 48 years * Participants with unilateral mastectomy * Females who have undergone radical or simple mastectomy * Participants with a previous history of stage I to III breast cancer * Patients who are at least 3 months post-surgery * Participants who have been treated with chemotherapy or radiotherapy
Exclusion criteria
* Metastatic cancer to the lung, bone, or any other surrounding organ or tissue. * Uncontrollable hypertension greater than 140/90 mmHg * Unstable cardiovascular disease, such as arrhythmias or unstable angina * Any other acute or chronic respiratory disease, such as chronic obstructive pulmonary disease (COPD), asthma, or tuberculosis (TB) * Multiple sclerosis or Guillain-Barré syndrome * Visual impairment or hearing loss that affects the efficiency of exercise
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pulmonary Function (FEV/FVC) Assessed by Spirometry | Baseline and 4 weeks | Pulmonary function will be assessed using spirometry, including forced vital capacity (FVC) and expiratory volume. The FEV/FVC ratio will be used to evaluate pulmonary function and changes following the intervention. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dyspnea Severity Assessed by Dyspnea Index | Baseline and 4 weeks | Dyspnea severity will be assessed using a 5-point Likert-based Dyspnea Index. Scores range from 0 to 40, with higher scores indicating greater severity of breathing difficulty. |
| Functional Mobility Assessed by Timed Up and Go Test | Baseline and 4 weeks | Functional mobility will be assessed using the Timed Up and Go (TUG) test. The participant will rise from a standard chair, walk approximately 3 meters, turn around, return to the chair, and sit down. Performance will be recorded in seconds. |
| Health-Related Quality of Life Assessed by SF-36 | Baseline and 4 weeks | Health-related quality of life will be assessed using the Short Form-36 Health Survey Questionnaire (SF-36), which evaluates overall health status and different aspects of physical and psychosocial well-being. |
Countries
Pakistan